Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.
Fenofibrate (300 mg daily) was given to 9 subjects (7 men, 2 women) with dysbetalipoproteinemia type III. The treatment brought about important plasma level reductions in cholesterol (-35%), triglycerides (-56%), VLDL-cholesterol (-63%) and VLDL-triglycerides (-59%). The VLDL-C/TG ratio, which was 0.40 before treatment, was 0.30 after 4 weeks of fenofibrate, still suggestive of type III. LDL-C, when measured by conventional methods, was unchanged but isolation of the IDL (1.006-1.019 g/ml) fraction from the 1.006 g/ml infranatant revealed that true LDL-C levels actually increased in 6 individuals while IDL-C decreased considerably. The total HDL-C increase was mostly due to a 33% HDL3-C change. Apolipoprotein levels were considerably modified, notably apo B, C-III and E which were decreased, as well as the lipoprotein particles containing combinations of these apolipoproteins, namely LpE:B and LpC-III:B. Apo A-I was slightly modified as LpA-I: A-II particle levels increased and LpA-I decreased. There were marked compositional modifications of apo B-containing lipoproteins which corresponded to changes of the whole lipoprotein profile. Some abnormal classes of lipoproteins (e.g., beta-VLDL, dense LDL), characteristic of this disease, tended to disappear and were in some cases replaced by material of different size and density.
Lussier-Cacan
S
S
Institut de recherches cliniques de Montréal, Québec, Canada.
Bard
J M
JM
Boulet
L
L
Nestruck
A C
AC
Grothé
A M
AM
Fruchart
J C
JC
Davignon
J
J
D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004586:Electrophoresis; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000032:analysis / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000627:therapeutic use*
D001053:Apolipoproteins; D008078:Cholesterol, LDL; D008055:Lipids; D008074:Lipoproteins; D011422:Propionates; D011345:Fenofibrate